The Finnish and Swiss B. pertussis PCR assays have been used nationwide in the two countries as routine diagnostic methods; thus, a large number of clinical specimens have been tested. This has provided an opportunity to analyze the significance of PCR results for clinical specimens from two populations with high pertussis vaccination coverage. In immunized populations, pertussis often presents mild or atypical symptoms, such as prolonged cough [2-5, 17, 18] , especially in school-age children and adults, and therefore, the diagnosis of B. pertussis infection is more difficult. The results obtained from the use of PCR for the diagnosis of pertussis in Finland and Switzerland are discussed, as are potential uses of PCR in studies of vaccine efficacy and epidemiology of B. pertussis infection.
Materials and Methods
Immunization and surveillance ofpertussis in Finland and Switzerland. In Finland, pertussis vaccination was introduced in 1952 [19] . The vaccine contains 5 X 10 9 formalin-killed B. pertussis combined with 20 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid per dose. Infants are vaccinated at 3, 4, and 5 months of age, and a booster dose is given at 2 years. In the early 1980s, .....,97% of children had been vaccinated with the 3 primary doses of B. pertussis vaccine [19] . In the 1990s, 99.7% of 3-year-olds have been vaccinated with the first 3 doses, and 98% have received the booster dose at 2 years of age [20] .
In Switzerland, the most widely used pertussis vaccine was registered in 1950 [21] . The vaccine contains 20 X 10 9 formalinkilled B. pertussis combined with 25 Lf of diphtheria toxoid and 10 Lf of tetanus toxoid per dose. The official vaccination recommendation used to be one dose at 3, 4, and 5 months of age. Since 1991, however, infants have been vaccinated at 2,4, and 6 months of age. No booster dose is used after primary vaccination. The vaccination coverage rate shows local variations but averages ....., 80% for all three doses [22] .
Despite high vaccination rates, B. pertussis infection remains epidemic and endemic in Finland and Switzerland. In Finland, the annual incidence has ranged from 8.4 to 51.6/1 00,000 population during the last 10 years, and the total annual number of pertussis cases has ranged from 423 to 2574. Most patients with confirmed B. pertussis infection are children of school age. In Switzerland, surveillance of B. pertussis infection was started in 1991 by the Swiss Sentinel Network [22] . The estimated annual incidence was 70/100,000 population in 1992 and 1993, 360/100,000 in 1994, and 290/100,000 in 1995. The estimated total number of pertussis cases was 4500.in 1992 and 1993,25,000 in 1994, and 20,000 in 1995. Of the pertussis cases reported from 1991 to 1995, 55% were children 1-8 years old; 75% of these children had received three doses of vaccine.
Clinical specimens in Finland. A total of 1904 NP specimens were tested in Finland. The specimens were obtained during local pertussis outbreaks (671 outbreak samples) and from samples sent for routine diagnosis to the Department of Medical Microbiology, University of Turku (1233 routine samples). All NP specimens, except 40 aspirates belonging to the outbreak samples, were collected on calcium alginate swabs. Aspirate specimens were obtained from persons 6 months to 76 years old.
First, 671 NP samples were obtained from November 1990 through March 1993 during several local pertussis outbreaks in western and southwestern Finland. Culture-confirmed B. pertussis infection was a key definition for the outbreaks. A prospective study was started after recognition of the first laboratory-confirmed cases. Samples were obtained from 286 males and 385 females; 10 were < 1 year old, 43 were 1-3, 56 were 4-6, 455 were 7-15, and 107 were :;::,:16. At the time of sampling, 412 subjects had cough with or without paroxysms, and 259 were asymptomatic contacts of persons with laboratory-confirmed B. pertussis infection. Serum samples for EIA were obtained from 304 subjects. Detailed information on the onset and severity of symptoms was available for 143 of the 304 subjects with both NP and serum samples.
Since April 1993, PCR has been used routinely in Finland to diagnose B. pertussis infection. The second set of samples studied was submitted to the PCR laboratory after this time point by local health centers and hospitals. Samples were routine NP swab specimens from 1233 persons with suspected pertussis; 333 patients were <1 year old, 194 were 1-3,190 were 4-6,363 were 7-15, and 153 were :;::':16. An average of41 samples (range, 7-123) was obtained each month. Of the 1233 NP samples, only 158 were tested by both culture and PCR.
For control samples, 257 swabs were obtained from 52 children with respiratory infections other than pertussis and from 205 healthy subjects under nonepidemic conditions. All control samples were tested by culture and PCR.
Clinical specimens in Switzerland. In Switzerland, PCR has proven specific and more sensitive than culture for the detection of B. pertussis infection [8, 9] . Since March 1994, PCR has been used routinely in the Microbiological Laboratory, University Children's Hospital, Basel, to diagnose pertussis. During an 18-month period, routine NP samples were obtained on Dacron swabs from 1890 patients suspected of having pertussis; 337 patients were < 1 year old, 615 were 1-3,546 were 4-6,335 were 7-15, and 57 were > 16. The samples were tested by PCR only. In Switzerland, confirmation of B. pertussis infection is based on positive culture or PCR results from NP specimens. The clinical definition is cough lasting >2 weeks together with a contact (in the family, at school, or during an epidemic) who is known to have B. pertussis infection [23] . For sporadic cases, whooping attacks or vomiting after a cough are needed for confirmation of diagnosis.
Laboratory methods in Finland. After collection, NP specimens in Finland were locally inoculated onto charcoal agar plates, placed in sterile empty tubes with caps, transported to the laboratory, and stored at -20°C until tested by PCR [12, 13] . The plates were incubated in a humid atmosphere at 35°C and inspected daily for 7 days to determine pertussis-like colony growth. Suspected colonies were stained with Gram's stain and studied by slide agglutination with antisera to B. pertussis. The identity of B. pertussis strains was confirmed by gas-liquid chromatography. In the study in which the colony counts on culture plates were compared with PCR positivity, all the cultures were done by an experienced technician.
DNA used for PCR was extracted and purified by phenol-chloroform. Primers derived from the repeated insertion sequence of B. pertussis were used, and 35 cycles were carried out. The DNA extracted from the prototype strain of B. pertussis was used as the positive control, and all reagents, except template DNA, were included in the negative control tube. Both positive and negative controls were included in each PCR run. The amplified products were separated by 2% agarose gel electrophoresis, and the bands were visualized as ultraviolet fluorescence after staining with ethidium bromide. The PCR products were further analyzed by Southern hybridization [13] . The sensitivity ofthe PCR assay was~5 bacteria per reaction tube. To avoid contamination during processing of specimens and amplified products, areas in which samples were processed (culture and pre-and post-PCR areas) were physically separated. The DNA from the prototype strain of B. pertussis was also used to test for possible inhibitory activity of the specimens [12] , but none was found (data not shown).
For EIA, IgG, IgA, and IgM to pertussis toxin, filamentous hemagglutinin, and pertactin of B. pertussis (provided by SmithKline Beecham Biologicals, Rixensart, Belgium) were measured [24] . Only 1 serum sample per patient was tested, and~50% of the samples were from persons who had had symptoms for <2 weeks.
Laboratory methods in Switzerland. After collection, NP swabs were sent to the laboratory in 400 p.L of NaCI (0.9%) [9] . The samples were lysed in lysis buffer and digested with 20 p.g/ mL proteinase K. DNA was extracted and purified with phenol-JID 1996; 174 (December) 
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Comparison of PCR, culture, and
EfA results in Finland. In Finland, 829 samples were tested by both culture and PCR: 64 (8%) of them were positive by culture, and 57 (89%) of those were also positive by PCR. Table 2 shows the corresponding figures for the outbreak samples: 7% were culture positive and 27% were PCR positive. Thirty-eight (84%) of the culture-positive cases were also positive by PCR. Of the 412 subjects with cough at the time of sampling, 43 (10%) were positive by culture and 105 (25%) by PCR. Of the 259 asymptomatic contacts at the time of sampling, 2 (0.8%) were positive by culture and 73 (28%) by PCR. One hundred twentysix asymptomatic contacts, 28 (26%) of whom had been PCR positive before follow-up, were followed for 6 weeks. Seven (25%) of the PCR-positive subjects developed typical pertussis 1-28 days after sampling.
The PCR positivity rate correlated with the number of B. pertussis colonies on plates: 9 samples had~10 colonies, 5 (56%) of which were positive by PCR; 17 had 11-100 colonies, 15 (88%) of which were positive by PCR; and 19 had > 100 colonies, 18 (95%) of which were positive by PCR.
PCR, culture, and EIA results also were compared for 304 Finnish subjects whose NP and serum specimens were obtained figure 1 ). The monthly incidence of PCR-positive pertussis cases was 5%-48% during this time period. Of the 257 control samples, none was positive by culture, and only 1 (0.4%) was positive by PCR (table 1) , for a PCR specificity of 99.6%.
In Switzerland, 1890 routine clinical samples were tested for B. pertussis by PCR, and 683 (36%) were positive (table  1) . Twenty-nine (3.3%) of the 868 control samples were positive by PCR, for a PCR specificity of 96.7% (table 1) . 16 . The percentage of PCR-positive specimens by age group was 31% in children < 1 year, 10% in children 1-3, 12% in children 4-6, 38% in children 7-15, and 9% in subjects ;:::16.
In Switzerland, the rate of PCR-confirmed cases by age group was 30% (102/337) in children <1 year old, 39% (241/ 615) in children 1-3, 36% (194/546) in children 4-6, 39% (131/335) in children 7-15, and 26% (15/57) in subjects ;:::16 (figure 1). The total percentage ofPCR-positive specimens was 15% in children < 1 year old, 35% in children 1-3, 28% in children 4-6,20% in children 7-15 years, and 2% in subjects ;::: 16. The rate of PCR-confirmed cases was statistically significantly higher in unvaccinated children (121/268) than in those who had received one or more dose of diphtheria-tetanus toxoid-pertussis vaccine (499/1315) (P = .033) (table 5).
The rate ofPCR-confirmed B. pertussis infections was statistically significantly higher in children 1-15 years old in Switzerland than in Finland (figure 1). The difference was most significant (P < .001) in the 1-to 3-year-old age group. PCR during outbreaks. There was laboratory evidence of B. pertussis infection in 123 cases (40%), 31 (25%) of which were confirmed by culture, 75 (61%) by PCR, and 70 (57%) by EIA. One case (0.8%) was confirmed by culture alone, 33 (27%) by peR alone, and 46 (37%) by EIA alone. The specimens of 46 subjects were positive by PCR but negative by culture. Of these, 13 already had been proven seropositive when the serum samples were tested.
Relationship between symptoms and laboratory test results in Finland and Switzerland. NP and serum samples and detailed information on the onset and severity of symptoms were available for 143 subjects from the Finnish outbreaks (table  3) . Sixty-seven subjects (47%) had laboratory-confirmed B. pertussis infection. The positivity of culture decreased more rapidly than that of PCR. The last positive culture result was obtained 5 weeks after onset of symptoms. In contrast, 25% of patients remained PCR positive for at least 6 weeks after emergence of symptoms. The positivity of EIA increased with time, as expected. Six weeks after onset of symptoms, 15 patients (63%) had a laboratory-confirmed diagnosis (PCR, EIA, or both) of B. pertussis infection: 13 (87%) were positive by EIA.
Of the 1890 Swiss subjects, 1589 had detailed data available regarding the onset and severity of symptoms at the time of sampling (table 4). More PCR-confirmed pertussis cases were identified among patients with cough with paroxysms (40%) than among patients with cough without paroxysms (27%) (P < .001). PCR positivity decreased with time after onset of symptoms; 23% of patients remained PCR positive for pertussis for at least 6 weeks after onset of symptoms.
PCR-corifirmed B. pertussis infection in different age groups in Finland and Switzerland.
In the Finnish routine sample material, the incidence of PCR-positive pertussis infection was highest (28%) in the 7-to l5-year-old age group (figure 1). The rate ofPCR-confirmed cases was 25% (84/333) in children Discussion Figure 2 . % of typical symptoms (grey bar), laboratory-confirmed asymptomatic infection (black bar), and laboratory-confirmed pertussis cases (white bar) by age group during pertussis outbreaks in I day care center and 2 elementary schools in Finland.
To our knowledge, the clinical population used in this study is the largest used to date for evaluation of PCR for the diagnosis of pertussis. Although several PCR assays have been developed for the diagnosis of B. pertussis infection and shown to possess a diagnostic sensitivity that is usually higher than that of culture [7 -16] , they were all evaluated on the basis of a limited number of clinical specimens. To prove its real benefit in pertussis diagnostics, PCR methodology has to be tested in a large number of clinical specimens, and interlaboratory evaluation of PCR results are also needed. The nationwide routine use of PCR for diagnosis of B. pertussis infection in Finland and Switzerland has provided an opportunity to analyze and compare the significance of PCR results for clinical samples.
The results presented in this paper clearly show that PCR is superior to culture in sensitivity: The PCR assays detected positive samples about four times more often than did culture. This figure is similar to that previously obtained in Swiss studies [8, 9] . The contribution of culture to this diagnostic efficacy was limited, since only 11% of culture-positive specimens were negative by PCR. These negative PCR results may be due to the fact that the specimen swabs were used for inoculation of culture plates prior to DNA extractions for PCR. If the swab originally contained only a few microbes, it is possible that none were left for PCR after plate inoculation. In contrast to the experience with older children and adults, our experience with young unvaccinated infants with pertussis is that the sensitivity of culture and PCR is similar, but PCR results in a faster diagnosis.
The Swiss and Finnish PCR assays have shown similar sensitivities in laboratory conditions (~5 bacteria/PCR run) [8, 9, 13] . Of interest, the frequency of PCR-positive samples was higher in the Swiss (36%) than in the Finnish (22%) samples. The difference might reflect a real epidemiologic difference of B. pertu ssis infection in the two countries. Lower vaccination coverage and non-use of booster doses in Switzerland compared with Finland might increase the pool of persons susceptible to B. pertussis infection.
In this study, PCR revealed fundamental differences in the age distribution of patients with B. pertussis infection in the two countries. In Switzerland, the highest incidence of infection was among 1-to 3-year-old children, whereas in Finland, the lowest incidence was among that age group. This difference may be due to the booster dose of vaccine that is given at 2 years of age in Finland. It is likely that a booster dose can postpone the peak incidence by~3-5 years [19] . This hypothesis is also supported by the fact that the incidence ofB. pertussis infection peaks in elementary school children in Finland, whereas in the United States, where a booster dose is given at 4-6 years of age, the peak occurs in teenagers and adults [2] . However, there may be other reasons for the difference in ages of patients with B. pertussis infection in Finland and Switzerland, such as differences in patient selection for PCR testing and in the use of antimicrobial prophylaxis and therapy.
Because of differences in severity of illness, it is probable that younger children are evaluated at an earlier stage of illness than older persons; thus , they would more likely have positive PCR results. This phenomenon, however, is most likely occurring in both Switzerland and Finland. Symptoms of pertussis, especially during the early stages of the disease, are unspe- In Finland, we also prospectively investigated local outbreaks of pertussis that occurred between November 1990 and March 1993 in schools and a day care setting. Table 2 shows the age distribution of Finnish subjects with outbreak samples PCR-positive for B. pertussis. Their ages were similar to those of Finnish subjects whose routine samples were PCR-positive for pertussis ( figure 1) .
Outcome ofB. pertussis infection in different age groups in Finland. During the communitywide pertussis outbreak in Finland, a day care center (29 children; age range, 1-6 years) and two elementary schools (210 pupils; 7-12 years old) were prospectively studied when culture-confirmed cases were identified in each of the three settings [4] . All children had received 3 primary doses of diphtheria-tetanus toxoid-pertussis vaccine, and 80% of the children in the day care center and 90% in the schools had also received a booster dose at 2 years of age .
Laboratory evidence of B. pertussis infection was obtained from 13 children (45%) at the day care center and 63 of the school children (30%) . The percentage of children presenting with typical pertussis symptoms and the percentage of laboratory-confirmed clinical cases increased with age (figure 2). In contrast, immunized children 4-6 years old who had been in close contact with others with culture-proven cases of B. pertussis infection usually had an asymptomatic infection, as detected by PCR. cific, and patients might receive antibiotics before a laboratoryconfirmed diagnosis. In Finland, the use of erythromycin is recommended in infants < 6 months of age when they come into contact with persons with pertussis. As far as we are aware, erythromycin has not been widely used as prophylaxis in older children or adults. The exact number of persons receiving treatment or chemoprophylaxis is unknown. In Switzerland, the use of erythromycin and cotrimoxazol is recommended to reduce the time of infectivity, and it is given at an early stage of pertussis infection for therapy. Chemoprophylaxis may be considered when susceptible children come into contact with untreated pertussis patients. The use of antibiotics in patients with pertussis can reduce the rate of B. pertussis isolation from them [25, 26] . However, PCR can identify B. pertussis infection more often than culture in patients who have already taken antibiotics [9, 27] .
Several genes of B. pertussis have been used as targets in PCR used for the diagnosis of pertussis. The two most common are the pertussis toxin promoter region and the repeated insertion sequences [7, 10, 11, 14] , which were also used in this study. Our study, which involved more clinical samples did other studies [7, 10, 11, 14] , provided further confirmation that these PCR assays have good sensitivity and specificity. Because of the high copy number, a PCR amplifying the repeated insertion sequence is theoretically more sensitive than that based on the toxin promoter region. In this study, however, the sensitivity of the pertussis toxin promoter-based PCR was higher than that of the insertion sequence-based PCR. The other two targets used in PCR for pertussis diagnosis are a DNA region upstream of the porin gene [15] and the adenylate cyclase toxin gene [16] . Clinical data suggest that the PCR based on the area near the porin gene provides sensitivity similar to that provided by our gene targets. Experience with the adenylate cyclase toxin PCR is still limited. In addition, this PCR assay does not distinguish between B. pertussis and Bordetella parapertussis.
Culture positivity is known to decrease rapidly after onset of pertussis. As expected, the same trend was seen in PCR positivity. However, PCR clearly remained positive longer than did culture. This can be explained by the fact that PCR, unlike culture, does not differentiate between dead and live organisms. Evidently, dead bacteria and their degradation products remain in the nasopharynx for some time after the active vegetation period [4, 12] .
PCR offers a definite time advantage over culture, because B. pertussis is a fastidious and slowly growing organism. Its cultivation usually takes 3-7 days, whereas the entire PCR procedure can be done in 1-2 days. Moreover, the time advantage offered by PCR shows its potential for an early and rapid diagnosis, which is important for effective prevention of transmission and therapy of B. pertussis infection.
The excellent sensitivity of PCR assays makes high demands on their specificity. PCR methods should be tested for crossreactions with large panels of different bacterial species. The PCR assays used in this study have proven definitely specific for B. pertussis: No other Bordetella species have tested positive [8, 12, 13] . However, final proof of the specificity of a diagnostic test can be obtained only by testing appropriate control materials. In this study, both healthy subjects and patients with respiratory infections other than pertussis served as controls. The specificities of the tests proved excellent in both Finland (99.6%) and Switzerland (96.7%).
In the PCR laboratory, proper controls for monitoring contamination from previous PCR amplifications and other samples are an important issue. The two laboratories in our study have physically separate culture and pre-and post-PCR areas, and several controls consisting of known and blinded negative samples and reagent controls were included in PCR runs. In Switzerland, the use of the uracil-DNA-glycosylase system further minimizes PCR product carry-over. Therefore, 1 Finnish control sample (0.4%) and 29 Swiss control samples (3.3%) in our study could be considered true rather than false positives. The difference may, however, reflect the fact that there is a larger amount of B. pertussis bacteria circulating among the population in Switzerland than in Finland, although B. pertussis infection is endemic in both countries. Furthermore, it is known that in immunized populations the disease often presents with mild and atypical symptoms [2-5, 17, 18] , and those cases presenting with mild symptoms can be identified by PCR [8] . Perhaps those subjects in our study with positive PCR results had already had mild symptoms or symptom-free infection and still served as "controls."
Asymptomatic B. pertussis infection is a controversial term. In an early study based on bacterial isolation, no "asymptomatic carriers" of B. pertussis were identified [28] . However, several later studies reported culture of the organism from asymptomatic contacts of patients with B. pertussis infection [29, 30] . Moreover, studies based on EIA have shown the phenomenon of asymptomatic infection [31, 32] . Our PCR results show that the asymptomatic infection exists and is not rare: 92% of the children with laboratory-confirmed B. pertussis infection in the day care center and one-third of the school children remained asymptomatic throughout the 6-week follow-up period. Whole-cell pertussis vaccines, in addition to providing protection, have been shown to modify the severity of clinical illness. It is evident that those remaining symptomfree have sufficient immunity provided by vaccines or natural boosters.
The combination of culture, PCR, and EIA proved B. pertussis infection in~50% of the patients who had had a paroxysmal cough for> 3 weeks and who had been in contact with a person with laboratory-confirmed pertussis. Thus, these patients met the World Health Organization criteria for clinical pertussis. This shows that even after the use of PCR, laboratory methods only have a supportive role in the diagnosis of typical pertussis. However, typical symptoms are not frequent among school children and adults, who show the highest incidence of B. pertussis infection in highly immunized populations, such as in Finland [2] [3] [4] [5] . In this population, the disease usually pres-ents with prolonged cough with or without paroxysms. Whooping, which otherwise characterizes pertussis, is not a common symptom.
Laboratory methods, including PCR, are important elements in the diagnosis of patients with atypical pertussis. Both the Swiss and Finnish PCR assays identified ---25% of patients with prolonged cough for at least 6 weeks after onset of symptoms. On the other hand, the diagnosis of atypical pertussis is important not only for the patients but also for unimmunized infants in contact with them. There is rather convincing evidence that patients with atypical pertussis serve as the main reservoir of transmission of B. pertussis to susceptible infants [3-5, 31, 32] .
Our results clearly show that PCR can substantially improve the possibilities of identifying these diagnostically problematic cases. About one-third of the Swiss patients with prolonged cough without paroxysms proved positive for B. pertussis infection by PCR. Patients with atypical pertussis are usually school children or adults. In this population, "atypical" pertussis rather than "classic" paroxysmal coughing may more typically be present. Clinicians should submit samples for testing even when encountering persons with rather prolonged cough (~3 weeks). Furthermore, because atypical pertussis results from waning immunity, it could be prevented and eliminated by booster immunization. The results of this study stress the importance of continuous booster immunization. Whole cell vaccines could be used in children up to school age, and acellular vaccines could be used for the booster or acellular vaccines could be used for both primary and booster immunizations.
We conclude that PCR is a sensitive, specific, and rapid assay for the diagnosis of B. pertussis infection. It can overcome many of the known limitations of culture, especially in countries with high vaccination coverage. peR can facilitate epidemiologic studies of B. pertussis infection, and the results can be taken into account in pertussis case definitions used for vaccine efficacy trials.
